

Risk factors for community transmission of SARS-CoV-2. A cross-sectional study in 116,678 people.

Eyrun F Kjetland

Oslo University Hospital: Oslo Universitetssykehus

Karl Trygve Kalleberg

Age Labs AS

Camilla Lund Søråas

Oslo University Hospital: Oslo Universitetssykehus

Bato Hammarstrøm

Oslo University Hospital: Oslo Universitetssykehus

Tor Åge Myklebust

Cancer Registry of Norway

Synne Jenum

Oslo University Hospital: Oslo Universitetssykehus

Eyrun Axelsen

Furst Medical Laboratory

Andreas Lind

Oslo University Hospital: Oslo Universitetssykehus

Roar Bævre-Jensen

Vestre Viken Hospital Trust: Vestre Viken HF

Silje Bakken Jørgensen

Akershus University Hospital: Akershus Universitetssykehus HF

Frank Olav Pettersen

Oslo University Hospital: Oslo Universitetssykehus

Lene B Solberg

Oslo University Hospital: Oslo Universitetssykehus

Cathrine Lund Hadley

Age Labs AS

Mette Istre

Oslo University Hospital: Oslo Universitetssykehus

Knut Liestøl

University of Oslo: Universitetet i Oslo

John Arne Dahl

Oslo University Hospital: Oslo Universitetssykehus

Giske Ursin

Cancer Registry of Norway

Arne Søråas (✉ arne@meg.no)

Oslo University Hospital: Oslo Universitetssykehus <https://orcid.org/0000-0003-1622-591X>

Research Article

Keywords: COVID-19, epidemiology, SARS-CoV-2, community dissemination, pandemic, risk factors

Posted Date: February 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-179906/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Risk factors for community transmission of SARS-CoV-2.

A cross-sectional study in 116,678 people.

Eyrun F. Kjetland*, Karl Trygve Kalleberg, Camilla Lund Søråas, Bato Hammarström, Tor Åge Myklebust, Synne Jenum, Eyvind Axelsen, Andreas Lind, Roar Bævre-Jensen, Silje Bakken Jørgensen, Frank Olav Pettersen, Lene B. Solberg, Cathrine Lund Hadley, Mette S. Istre, Knut Liestøl, John Arne Dahl, Giske Ursin, Arne Søråas*

*Co-corresponding authors:

Dr Arne Søråas. Department of Microbiology, Oslo University Hospital, Post box 4950 Nydalen, 0424 Oslo, Norway. E-mail: arvsoe@ous-hf.no Phones: +47 90652904

Professor Eyrun F. Kjetland. Department of Microbiology, Oslo University Hospital, Post box 4950 Nydalen, 0424 Oslo, Norway. E-mail: e.f.kjetland@medisin.uio.no Phones: +47 97 00 85 79/+27 76 4920 800

Author affiliations

Department of Microbiology, Oslo University Hospital, Oslo, Norway (EF Kjetland PhD, S Jenum PhD, FO Pettersen PhD); Discipline of Public Health Medicine, Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa (EF Kjetland PhD); Age Labs AS, Oslo, Norway (KT Kalleberg PhD, C Lund Hadley PhD, AV Søråas PhD); Cancer Registry of Norway, Oslo, Norway (TÅ Myklebust PhD, G Ursin); Dept of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (G Ursin PhD); Dept. of Preventive Medicine, University of Southern California (USC), Los Angeles, Calif, USA (G Ursin PhD); Department of Research and Innovation, Møre and

Romsdal Hospital Trust, Ålesund, Norway (TÅ Myklebust PhD), Department of Environmental and Occupational Medicine, Oslo University Hospital (C Lund Søråas PhD, B Hammarström PhD); Først Medical Laboratory, Oslo, Norway (E Axelsen PhD); The Department of Microbiology, Oslo University Hospital, Oslo, Norway (A Lind PhD, JA Dahl PhD, AV Søråas PhD); Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway (LB Solberg PhD); Department of Medical Microbiology, Vestre Viken Hospital Trust, Drammen, Norway (R Bævre-Jensen MD); Department of Informatics, University of Oslo, Oslo, Norway (K Liestøl PhD); Department of Clinical Microbiology and Infection Control, Akershus University Hospital, Norway (SB Jørgensen PhD)

Abstract

Background

The risk factors for SARS-CoV-2 transmission are not well characterised. We sought to identify potential risk factors for transmission and actionable information that can be used to prevent SARS-CoV-2.

Methods

Individuals tested for SARS-CoV-2 at four accredited laboratories were invited. In addition, participants were recruited through a media campaign. Self-reported SARS-CoV-2 test results were compared with laboratory results, demographic data and behavioural facts were collected using a digital platform. In a cross-sectional design positive cases were compared with negative and untested control groups.

Findings

Approximately 14 days after a countrywide lockdown in Norway, 116,678 participants were included. Median age was 46 years, 44% had children in preschool or in school; 18% were practicing health professionals. International flights, contact with infected individuals, and gatherings of more than 50 people, were associated with increased risk of testing positive. Health professionals who treated COVID-19 patients were at higher risk of testing positive than those who did not. Having undergone light infections, the last six months was strongly associated with lower odds ratio of SARS-CoV-2 positivity. Contact with children, use of hand sanitiser and use of protective gloves in private were also associated with lower odds ratio of testing positive for SARS-CoV-2.

Interpretation

Further research is needed to explore if being a parent or looking after children is associated with lower risk of SARS-CoV-2 positivity in the next phases of the pandemic. Immunological research should be done to determine the effects of prior trivial infections on SARS-CoV-2

infection. We confirm that large gatherings during the pandemic should be avoided and those who are infected, or under suspicion thereof, posed very high risks to others in this population.

Registration:

Trial registration: ClinicalTrials.gov: NTC 04320732, March 25, 2020.

Keywords

COVID-19, epidemiology, SARS-CoV-2, community dissemination, pandemic, risk factors

Declarations

Funding

The salaries of Dr. Kalleberg, Dr. Arne Søråas, and Dr. Catherine Lund Hadley were partly or wholly funded by the company Age Labs AS.

Other authors declare no specific funding.

Declaration of interests

Dr. Kalleberg, Dr. Arne Søråas, and Dr. Catherine Lund Hadley report other from Age Labs AS, outside the submitted work. Other authors declare no conflicts of interest.

Data sharing

Data sharing is restricted by the informed consent form, the ethical approval committee and the European General Data Protection Regulation (GDPR). Upon request, in agreement with the above, the PI may be able grant partial access to an anonymized data set.

Authors' contributions

AS, CLS, JAD and KTK designed the study.

AS, CLS, CLH, SJ, FOP, BH, JAD, MI and KTK designed the questionnaire.

AS, KTK, LBS, EA, AL, RB, EFK, SBJ and MI recruited participants and administered the data collection.

TÅM, EFK, AS, GU, KL and KTK performed data cleaning, statistical analysis and interpretation.

EFK, AS, KTK, GU, ER, BH, MI, CLH, CLS, SJ, FOP, EA, LBS, RB, SBJ, KL, JAD and TÅM wrote the article. All authors reviewed and approved the article before submission.

Ethics approval and consent to participate

The study was approved by the Norwegian ethics committee (REK 124170) and followed the Helsinki Declaration. It was registered in ClinicalTrials.gov (NTC 04320732). All participants were given information about the study, and their right to withdraw from the study at any time. Consent forms were signed electronically, withdrawals/refusals likewise. Data collection and storage was administered through the University of Oslo Services for Sensitive Data.

Introduction

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes COVID-19, a potentially fatal disease. At the time of writing, more than almost 75 million people are infected and 1.6 million deaths have been reported in 187 countries.¹ The World Health Organisation (WHO) declared COVID-19 a pandemic March 11th 2020.²

In China, where the virus was first detected, a massive lockdown of society led to control of the number of COVID-19 cases.^{3,4} In South Korea, closure of schools and other protective measures have interrupted viral transmission.⁵ Strategies such as physical distancing, quarantine of exposed individuals such as travellers, school closures, cessation of large gatherings, and closures of restaurants have been implemented in many countries.⁶

Norway was one of the first Western countries to have a substantial outbreak. The population-wide digital literacy makes the country suitable for a secure, large-scale study in pandemic circumstances. With the aim to guide health policy, we sought to explore the community and health professional risk factors for SARS-CoV-2 acquisition.

Materials and methods

Study area and population

The study period was January 1st to April 6th 2020. Study participants were based in Norway, which has a population of 5.4 million people. The Gross Domestic Product (GDP) per capita was USD 92,121 in 2018, whilst the European GDP was USD 43,188.⁷ There are 22.4 practicing nurses and doctors per 1,000, which is the highest amongst the OECD countries (Organisation for Economic Co-operation and Development).⁸ There is high computer literacy, universal free health care, and most health care professionals in the capital city region commute to work by public transport. As shown in Figure 1, March 13th the authorities instituted a lockdown which entailed closure of schools, preschools, restaurants, entertainment, and public gatherings,

authorities retracted entry visas and dismissed foreigners at the borders. The population was asked to practice two metre physical distancing, work from home and avoid public transport. Eligible study participants were 18 years or older, had a Norwegian identification number, and electronic access to the national two-factor electronic login system; which is used to access all digital government services.

Study design and case definition

As shown in Figure 1 the availability of the SARS-CoV-2 PCR test varied in the study period. Figure 2 shows the cross-sectional study design. SARS-CoV-2 positive cases will be compared, firstly with those who had symptoms of COVID-19, but a negative test (denoted negative controls) and, secondly, with those untested who were sampled by convenience (denoted untested volunteer controls). The study was based on two recruitment strategies:

1) Invited (Figure 2A): Between March 27th and April 4th invitations were sent by cellular (cell) phone text message to individuals (n=23,948) who had been tested for SARS-CoV-2 at the Oslo University Hospital, Vestre Viken Hospital, or Fürst laboratories, three of the largest laboratories in and near Oslo. There was high agreement between self-reported and laboratory-reported SARS-CoV-2 PCR results (Kappa 0.99).

2) Volunteers (Figure 2B): From March 28th, the general population was invited through the Oslo University Hospital Facebook page and the study received nationwide media coverage. Anyone living in Norway was encouraged to participate. As shown in Figure 3 there was high agreement between the geographic study participant distribution and the dissemination of the disease in Norway. Furthermore, there was high agreement between self-reported and laboratory-reported SARS-CoV-2 PCR results (Kappa 0.97) for the 508 tested volunteers for whom we could confirm test results (Supplement 1).

Data collection

Using a secure digital platform, available through smartphones and computers, participants were asked to complete an online questionnaire on travel history, exposure to known COVID -19 cases, living arrangements, history of disease, self-reported test results and demographic variables. Participants were questioned about their behaviour in the two-week period before the lockdown or, if applicable, before they fell ill/were tested. They were asked about having undergone “light infections” in the past six months, a term implying respiratory tract infections or cystitis not requiring hospitalisation or antibiotics.⁹

SARS-CoV-2 RT-PCR method

SARS-CoV-2 sampling and detection was done according to official national guidelines.²² A combined nasopharyngeal and oropharyngeal specimen collected by a health professional and transported to the lab in liquid Amies transport medium where detection of SARS-CoV-2 was done by a reverse transcription polymerase chain reaction (RT-PCR) protocol. All participating laboratories were accredited.

For brevity, only a the Vestre Viken HF method for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) protocol is included described in detail: Nucleic acid extraction was performed with either MagNA Pure 96 using “MagNA Pure 96 DNA and Viral Small Volume Kit” (Roche) or MagNA Pure LC 2.0 using “MagNA Pure LC Total Nucleic Acid Isolation Kit High Performance” (Roche). RT-qPCR was performed in a duplex assay, including RNase P for internal control on a Lightcycler® 480 II (Roche) targeting the E gene in accordance with Corman et al., using either qScript XLT One-Step RT-qPCR ToughMix (Quantabio) or LightCycler® Multiplex RNA Virus Master (Roche).²³

Statistical considerations

Statistical analyses were carried out accordingly. In brief, we compared demographic facts and risk factors between cases and controls. Bivariate and multivariable odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated as measures of relative risk using logistic regression. Age and sex were considered mandatory confounders and included in all multivariable analyses. A list of potential risk factors was made *a priori* and included in the first round of multivariable analysis. Risk factors with no apparent association with the outcome (ORs very close to 1), were removed from the final model. Statistical significance of the risk factors was assessed using standard likelihood-ratio tests.

In the early phase of the pandemic SARS-CoV-2 PCR tests were widely available for any subject with a suspicion of COVID-19 disease. However, as shown in Figure 1, from March 13th, testing was restricted. Only patients potentially requiring hospitalisation, and symptomatic health professionals, were tested. Therefore, separate analyses were done for health professionals. The first cases in Norway had been on ski vacation in Italy or Austria. We consequently performed sensitivity analyses excluding the skiers and those reporting close contact with COVID-19 cases (Supplement 3). No formal mathematical correction was made for multiple comparisons. Data was analysed using SPSS version 26 (IBM Corp, New York, USA) and Stata version 16.0 (Stata Corp LLC, Texas, USA).

Ethical considerations

The study was approved by the Norwegian ethics committee (REK 124170) and followed the Helsinki Declaration. It was registered in ClinicalTrials.gov (NTC 04320732). All participants were given information about the study, and their right to withdraw from the study at any time. Consent forms were signed electronically, withdrawals/refusals likewise. Data collection and storage was administered through the University of Oslo Services for Sensitive Data.

Role of the funding source

The Age Labs had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Results

In the course of 11 days 116,678 participants were included, 52% were from the greater Oslo region, the epicentre of the epidemic in Norway (Figure 3). Those who had been tested in one of four laboratories of the greater Oslo region represented 6.7% (7839) of the study population. The rest (93.3%) were sampled by convenience as shown in Figure 2B. The time between testing and baseline (inclusion) was on average 13 days (SD=7 days). The cases and two control groups were well matched for age and chronic diseases such as hypertension and diabetes as shown in Table 1. Median age was 46 years (range 19-101), only 3.8% were above the age of 65 years, 71% of the study population (82,948) were female, among negative controls 78% were female (8,497/10,581). There was a median of 3 people (range 1-7) in each household, 44% (51,246) had children, 37,784 in preschool (age 0-5 years) and 38,586 in schools (6 – 19 years), 25,124 had children in both categories. One third lived in apartments, 2-3 % had diabetes, 10-13% reported hypertension, one in five had dogs and almost as many had cats. Health professionals, with and without patient contact, constituted 24% (27,567) of the study participants (Supplement 2).

Risk factors for SARS-COV-2 in 116.678 Norwegians

The final multivariable model included: age, sex, contact with infected individuals, chronic and other diseases, healthcare use, previous light infections, smoking, fitness, frequency of food shopping, public transport use, international flights, exposure to crowds, having children, contact with children, pets, meeting people at work, working with people, hand wash, hand sanitiser and use of gloves.

Table 2 compares cases with negative controls and untested volunteer controls. Having been on an international flight, and having had contact with a suspected or a confirmed COVID-19 case, was highly associated with SARS-CoV-2 positivity, in both control groups. Attending gatherings of more than 50 people was associated with a higher risk of SARS-CoV-2 positivity, whereas smaller gatherings were not. Those who used hand sanitiser or protective gloves privately had lower odds of SARS-CoV-2 positivity.

Interestingly, having undergone “light” infections the last six months was strongly associated with lower odds ratio of SARS-CoV-2 positivity (Table 2). Contact with other people’s children or having children of your own (in preschool or in school), meeting multiple colleagues at work, and owning pets were also associated with a lower odds ratio of testing positive in comparison with both control groups.

The cases reported to have visited grocery stores fewer times than the controls the two weeks before a positive test. Unexpectedly, the cases reported to be more fit than the controls. This finding remained after the skiers who had been to Austria and Italy had been excluded from the analyses.

Table 2 shows that the two control groups yielded similar results, however, those who said they were working with clients, pupils or patients were found to have less SARS-CoV-2 compared with negative controls, but more SARS-CoV-2 than the untested. This effect disappeared in the analyses with health professionals only, whilst other aspects of the analyses remained unchanged (Table 3a).

Parents, teachers, childminders and pet owners

Having been in contact with other people’s children, or having children of your own, was associated with lower odds of SARS-CoV-2 positivity. In a separate analysis, parents of preschool children were found to have a lower odds of SARS-CoV-2 compared to others (Adj. OR 0.79, 95% CI 0.62-1.0), and likewise school children, even the older age groups, did not pose an increased risk for their parents (Adj. OR 0.83, 95% CI 0.69-0.99). The lack of risk in being a

parent was also observed among health professionals. Neither having a cat (Adj. OR 0.84, 95% CI 0.67-1.07) nor a dog (Adj. OR 0.82, 95% CI 0.67-1.01) were risk factors for SARS-CoV-2.

Risk factors for SARS-CoV-2 in health professionals.

Practicing health professionals with patient contact constituted 18% (21,123) of the study population but 55 % of the tested individuals (7,642/11,608), $p < 0.001$, as per official testing policy (Supplement 2). Thirteen percent (2,722/21,054) of the tested health professionals suspected or knew that they had been exposed to a confirmed COVID-19 case compared to 7% (6,314/89,190) of the untested (OR 1.83, 95% CI 1.75-1.90). Furthermore, working in wards treating COVID-19 patients was associated with SARS-CoV-2 positivity both compared to SARS-CoV-2 negative and untested health professionals (Table 3b). There was no adverse effect in having children or having pets in this group. Among health professionals, there was a protective effect of washing hands more than seven times a day.

Use of public transport was significantly associated with SARS-CoV-2 positivity among health professionals (Table 3a). These effects remained unchanged when skiers (who had visited Austria/Italy) were removed.

Sensitivity analyses

We performed sensitivity analyses where we excluded individuals who had been in close contact with infected, “skiers” (i.e. travellers to Austria and Italy), and health professionals (i.e. tested through the study period if they had symptoms) (Supplement 3). The above findings remained largely unchanged; the sample size was low (144 cases). Neither taking out the skiers, nor stratifying the controls on being formally invited versus recruited through mass media, changed the results (Supplement 3, Table 2).

Discussion

This study indicates that being a parent, looking after children, and having pets were

significantly associated with a lower risk of SARS-CoV-2 positivity. Furthermore, those who reported having undergone light infections in the last six months were less likely to test positive. The use of hand sanitiser was protective and health professionals who washed their hands more than seven times per day had significantly less SARS-CoV-2 infection. International travel, close contact with an infected person, and participation in large gatherings were highly associated with increased risk of SARS-CoV-2 positivity. Public transport risk was independent of dose (frequency) and was a risk factor for health professionals, likely because they have to travel in the rush hours.

The effect of children and pets on the risk of SARS-CoV-2 could be related to having been regularly exposed to low or non-pathogenic strains of the *Coronaviridae* family previously, possibly establishing some immunity to the disease through cross-reacting antibodies, mucosal immunity or enhanced nonspecific viral immunity.¹⁰ Most light infections were likely upper respiratory tract viral infections, some of which might have been caused by members of the *Coronaviridae* family.¹⁰ We may speculate that such infections can induce resistance to SARS-CoV-2 infection, and/or ease COVID-19 disease.¹⁰ Having pets may induce changes to microbiome diversity and, likewise, induce immunological modulation, although research in this area is limited.¹¹ The indicators of social connectedness were robustly and negatively associated with SARS-CoV-2 positivity. The possible protective effects of having undergone light infections, before the pandemic, is consistent with this hypothesis and, likewise, robustly confirmed in all analyses.

However, the “protection” received through contact with children could also have to do with behaviour that was not recorded in this study, such as parents may possibly socialise less with strangers, than non-parents.¹² Furthermore, most of the positive participants were infected early in the pandemic in Norway. The virus was largely brought to the country by adults returning from ski-vacation in high prevalence areas and dissemination among children might occur at a later stage of the pandemic.

The main limitation of the study is that we tested fewer than 12.000 of the study population. Health professionals were tested widely throughout the study period. However, having COVID-19 symptoms was a prerequisite for testing in all phases and we could only do a cross-sectional study. Due to the test policy, most of the negative controls were health professionals with other respiratory tract infections. Many other respiratory tract infections are transmitted in the same way as COVID -19. In terms of risk factors, the negative controls were therefore similar to the SARS-CoV-2 positive cases and some genuine risk factors probably did not reach significance in this comparison. We therefore included the untested group as a second control group of mostly healthy individuals. However, the difference between the untested and the background population was not determined and there are likely biases. Furthermore, less than 40% of the tested, invited individuals participated. Therefore, this study represents a conservative estimate of risk factors for SARS-CoV-2.

Old age and a number of clinical conditions associated with old age are risk factors for severe disease.¹⁵ This study recruited and asked questions on a digital platform. Although more than 69% of those aged 65-70 years in Norway use the internet on average one hour per day less than five percent of the study participants were above the age of 65 years.¹⁶ We cannot preclude that they represent those who were too ill to participate in a study. Similarly, very few of our participants were immigrants, refugees, or had been hospitalised, indicating that our data is skewed towards those less affected by SARS-CoV-2. Hard copy questionnaires or face-to-face interviews may be necessary to engage these sub-populations. Behavioural risk factors in this study may therefore not be applicable for those with severe disease, those who do not speak Norwegian, are unable to use digital media, and the oldest age group. Furthermore, study results cannot necessarily be extrapolated to other stages of the pandemic. However, for those who were included, the comprehensive questionnaire was fully completed by the vast majority of the participants and most submitted their responses less than three weeks after lockdown, indicating that information on pre-lockdown behaviour may be reliable and that the study describes viral

dissemination in a susceptible population almost completely without any societal countermeasures.

Having had contact with a likely or a confirmed case of COVID-19 posed the highest risk of acquiring SARS-CoV-2. Restrictions on large gatherings and all gatherings that may involve contact with infected as well as restrictive travel recommendations seem warranted.

Based on our results, we recommend continued injunction on large gatherings during the pandemic. Furthermore, well-placed and free hand sanitizer in public places and persistent cleaning with soap and water where hands may touch surfaces may be relatively inexpensive and probably very efficient in preventing SARS-CoV-2 infection. Importantly, further research is needed to confirm whether children and social interaction can induce resistance to SARS-CoV-2 in other settings and in the next phases of the pandemic.

Acknowledgements

We thank Dagfinn Bergsager, Stein-Erik Lund, Milen Kouylekov, Olaug Reiakvam, and Roy Farai Manyaira for their help with data collection, manuscript preparation or submission. We thank the Age Labs AS for allowing AS, KTK and CLH to work on this project.

References

- 1 Johns Hopkins University. Johns Hopkins Coronavirus Resource Center. 2020.
<https://coronavirus.jhu.edu/map.html> (accessed April 27, 2020).
- 2 WHO Director General’s opening remarks at the-media briefing on Covid-19. 2020.
<https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (accessed March 12, 2020).
- 3 Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020; published online Feb 29. DOI:10.1016/S0140-6736(20)30260-9.
- 4 Chen S, Yang J, Yang W, Wang C, Bärnighausen T. COVID-19 control in China during mass population movements at New Year. *Lancet* 2020; **395**: 764–6.
- 5 Jiang S, Li Q, Li C, *et al.* Mathematical Models for Devising the Optimal SARS-CoV-2 Eradication in China, South Korea, Iran, and Italy. *SSRN Electron J* 2020; published online April 2. DOI:10.2139/ssrn.3559541.
- 6 Ferguson NM, Laydon D, Nedjati-Gilani G, *et al.* of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. DOI:10.25561/77482.
- 7 Trading Economics. Trading Economics. Econ. Heal. Indic. 2020.
<https://tradingeconomics.com/italy/indicators> (accessed March 28, 2020).
- 8 OECD INDICATORS. 2019; : 239.
- 9 Brinkhues S, Schram MT, Hoebe CJPA, *et al.* Social networks in relation to self-reported symptomatic infections in individuals aged 40-75 - the Maastricht study -. *BMC Infect Dis* 2018; **18**: 300.
- 10 Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017; **39**: 529–39.
- 11 Shi J, Wen Z, Zhong G, *et al.* Susceptibility of ferrets, cats, dogs, and other domesticated

- animals to SARS–coronavirus 2. *Science* (80-) 2020; : eabb7015.
- 12 Cohen S, Doyle WJ, Skoner DP, Rabin BS, Gwaltney Jr. JM. Social Ties and Susceptibility to the Common Cold. *J Am Med Assoc* 1997; **277**: 1940.
- 13 Glauser W. Proposed protocol to keep COVID-19 out of hospitals. *Can Med Assoc J* 2020; **192**: E264–5.
- 14 Verity R, Okell LC, Dorigatti I, *et al.* Articles Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020. DOI:10.1016/S1473-3099(20)30243-7.
- 15 Young BE, Ong SWX, Kalimuddin S, *et al.* Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. *JAMA - J Am Med Assoc* 2020; **323**: 1488–94.
- 16 Percentage internet users and minutes used for internet an average day, by group of population, contents and year. Statbank Norway.
<https://www.ssb.no/en/statbank/table/04519/tableViewLayout1/> (accessed April 23, 2020).
- 17 Isolate at home if sick. www.ecdc.europa.eu/en/novel-coronavirus-china (accessed May 6, 2020).
- 18 Gandhi M, Yokoe DS, Havlir D V. E d i t o r i a l Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. 2020.
DOI:10.1056/NEJMoa2008457.
- 19 Nussbaumer-Streit B, Mayr V, Dobrescu AI, *et al.* Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane database Syst Rev* 2020; **4**: CD013574.
- 20 Norwegian Institute of Public Health. Daily COVID-19 brief. 2020.
<https://www.fhi.no/sv/smittsomme-sykdommer/corona/dags--og-ukerapporter/dags--og-ukerapporter-om-koronavirus/>.
- 21 Norwegian Directorate of Health. Daily recommendations on COVID-19. 2020.

<https://www.helsedirektoratet.no/tema/beredskap-og->

[krisehandtering/koronavirus/anbefalinger-og-beslutninger](https://www.helsedirektoratet.no/tema/beredskap-og-krisehandtering/koronavirus/anbefalinger-og-beslutninger) (accessed April 7, 2020).

22. Health NIOP. Koronavirus-prøvetaking. <https://www.fhino.nettpub/coronavirus/testing-og-oppfolging-av-smittede/provetaking/> 2020.
23. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 2020;25:2000045.

Table 1. Study population characteristics

	Positive cases	Negative controls	Untested volunteer controls
	n=1,099 (%)	n=10,615 (%)	n=104,582 (%)
Mean age in years (Standard Deviation, SD)	47.4 (13.9)	44.2 (12.9)	46.6 (13.8)
Female	645/1,095 (56)	8,297/10,581 (78)	65,469/104,346 (70)
Close contact with infected§	637/1,090 (58)	1,371/10,556 (13)	2,908/104,115 (3)
Close contact with likely infected§	546/1,062 (51)	1,375/10,545 (13)	7,385/104,360 (7)
Chronic disease(s)	278/1,099 (25)	3,144/10,615 (30)	27,455/104,582 (26)
Other disease(s)	167/1,048 (16)	2,570/9961 (26)	22,752/98069 (23)
Monthly visit(s) to health services	161/1,098 (15)	2,521/10,594 (24)	21,559/104,469 (21)
Light infection(s) the last 6 months	565/1,097 (52)	8,885/10,603 (84)	68,847/104,442 (66)
Smoker (Past or current)	408/1,083 (38)	4,543/10,501 (43)	48,218/103606 (47)
Fitness: Good	548/1,098 (50)	3,520/10,606 (33)	34,922/104,496 (33)
Medium	508/1,098 (46)	6,151/10,606 (58)	60,276/104,496 (58)
Poor	42/1,098 (4)	935/10,606 (9)	9,298/104,496 (9)
Visit to grocery store: 0 - 3 times*	530/1,091 (49)	3,161/10,545 (30)	27,499/104,449 (26)
4 - 10 times*	515/1,091 (47)	6,508/10,545 (62)	66,090/104,449 (63)
More than 11*	46/1,091 (4)	876/10,545 (8)	10,860/104,449 (10)
Use of public transport: Not once*	438/1,090 (40)	4,520/10,549 (43)	47,003/104,405 (45)
1 - 3 times*	296/1,090 (27)	2,412/10,549 (23)	23,598/104,405 (23)
4 - 10 times*	201/1,090 (18)	1,684/10,549 (16)	16,667/104,405 (16)
More than 11*	155/1,090 (14)	1,933/10,549 (18)	17,137/104,405 (16)
International flight(s)*	397/1,091 (36)	1,697/10,535 (16)	10,637/104,248 (10)
In crowd(s) of 10-50 people*	855/1,089 (79)	8,322/10,519 (79)	78,432/104,281 (75)
In crowd(s) of more than 50 people*	606/1,090 (56)	5,003/10,541 (47)	48,218/104,331 (46)
Mean number of children at home (SD)	0.70 (1.02)	0.92 (1.09)	0.78 (1.03)
Contact with other's children*	519/1,086 (48)	6,827/10,542 (65)	62,981/104,450 (60)
Pet (cat, dog or other) in household	331/1,099 (30)	4,092/10,615 (39)	38,816/104,582 (37)
Regularly meet people at work	985/1,095 (90)	10,264/10,603 (97)	99,108/104,413 (95)
Work with pupils, clients or patients	360/1,099 (33)	6,377/10,615 (60)	27,633/104,582 (26)
Wash hands 7 times or more per day	847/1,096 (77)	9,310/10,604 (88)	81,715/104,463 (78)
Regularly use hand sanitiser	729/1,096 (67)	9,397/10,597 (89)	77,305/104,426 (74)
Use gloves in private for protection	218/1,082 (20)	3,131/10,566 (30)	36,234/104,127 (35)
Other characteristics			
Hypertension	108 (10)	1,084 (11)	12,323 (13)
Diabetes	24 (2)	305 (3)	2,915 (3)
Live in a flat (shared lift/staircase/foyer)	416 (38)	3,819 (36)	35,194 (34)
Work in home office	178 (16)	1,560 (15)	26,937 (26)
Work in office landscape	314 (29)	2,076 (20)	25,409 (24)
Retired	48 (4)	264 (3)	6,789 (7)
Health professional	319 (29)	7,395 (71)	19,853 (19)
Daily patient contact (professionals)	219 (69)	4,599 (63)	10,435 (53)
Symptom(s)*			
Fever	769 (70)	3,236 (31)	10,119 (10)
Cough	789 (72)	6,184 (58)	25,748 (25)
Sore throat	506 (46)	6,626 (62)	30,158 (29)
Changed sense of smell or taste	766 (70)	1,027 (10)	4,840 (5)
Household member had symptom(s)**			
Fever	445 (41)	1,888 (18)	11,673 (11)
Cough	510 (46)	4,108 (39)	27,563 (26)
Sore throat	362 (33)	3,769 (36)	25,308 (24)
Changed sense of smell or taste	373 (34)	476 (5)	3,079 (3)

Denominator varies as not all answered all questions

§the last 3 weeks before symptoms

*the last 2 weeks before symptoms or before lockdown

Table 2. Bivariate and multivariable analysis for SARS-CoV-2 risk factors.

	Bivariate	Multivariable		Bivariate	Multivariable	
	Positive cases vs Negative controls	Positive cases vs Negative controls	P-	Positive cases vs Untested volunteer controls	Positive cases vs Untested volunteer controls	P-
	OR (95% CI)	Adj. OR (95% CI)	value	OR (95% CI)	Adj. OR (95% CI)	value
Age in years	1.02 (1.01 - 1.02)	1.01 (1.00 - 1.01)	0.123	1.00 (1.00 - 1.01)	1.01 (1.00 - 1.02)	0.001
Male sex	2.84 (2.49 - 3.22)	1.52 (1.27 - 1.81)	<0.001	1.86 (1.65 - 2.09)	1.51 (1.30 - 1.76)	<0.001
Close contact with infected§	9.4 (8.3 - 10.8)	4.56 (3.76 - 5.54)	<0.001	48.9 (43.2 - 55.5)	24.4 (20.3 - 29.4)	<0.001
Close contact with likely infected§	7.06 (6.18 - 8.06)	3.13 (2.57 - 3.81)	<0.001	13.9 (12.3 - 15.7)	2.80 (2.32 - 3.37)	<0.001
Chronic disease(s)	0.80 (0.70 - 0.93)	0.94 (0.76 - 1.14)	0.514	0.95 (0.83 - 1.09)	1.21 (1.01 - 1.44)	0.043
Other disease(s)	0.55 (0.46 - 0.65)	0.72 (0.58 - 0.91)	0.004	0.63 (0.53 - 0.74)	0.78 (0.63 - 0.95)	0.014
Monthly visit(s) to health services	0.55 (0.46 - 0.65)	0.84 (0.66 - 1.07)	0.154	0.66 (0.56 - 0.78)	1.17 (0.94 - 1.45)	0.162
Light infection(s) the last 6 months	0.21 (0.18 - 0.23)	0.29 (0.24 - 0.34)	<0.001	0.55 (0.49 - 0.62)	0.61 (0.53 - 0.71)	<0.001
Smoker (Past or current)	0.79 (0.70 - 0.90)	0.87 (0.73 - 1.04)	0.119	0.69 (0.61 - 0.79)	0.82 (0.71 - 0.96)	0.012
Fitness: Good	1	1		1	1	
Medium	0.53 (0.47 - 0.60)	0.78 (0.66 - 0.92)		0.54 (0.48 - 0.61)	0.72 (0.62 - 0.84)	
Poor	0.29 (0.21 - 0.40)	0.49 (0.33 - 0.74)	<0.001	0.29 (0.21 - 0.39)	0.48 (0.33 - 0.69)	<0.001
Visit to grocery store: 0 - 3 times*	1	1		1	1	
4 - 10 times*	0.47 (0.42 - 0.54)	0.66 (0.55 - 0.78)		0.40 (0.36 - 0.46)	0.57 (0.49 - 0.66)	
More than 11 *	0.31 (0.23 - 0.43)	0.46 (0.31 - 0.68)	<0.001	0.22 (0.16 - 0.30)	0.32 (0.22 - 0.45)	<0.001
Use of public transport: Not once*	1	1		1	1	
1 - 3 times*	1.27 (1.08 - 1.48)	1.15 (0.94 - 1.42)		1.35 (1.16 - 1.56)	1.15 (0.96 - 1.39)	
4 - 10 times*	1.23 (1.03 - 1.47)	1.01 (0.79 - 1.29)		1.29 (1.09 - 1.53)	1.02 (0.83 - 1.27)	
More than 11*	0.83 (0.68 - 1.00)	0.93 (0.72 - 1.21)	0.387	0.97 (0.81 - 1.17)	0.91 (0.72 - 1.14)	0.215
International flight(s)*	2.98 (2.61 - 3.41)	1.85 (1.53 - 2.25)	<0.001	5.03 (4.44 - 5.70)	3.60 (3.06 - 4.25)	<0.001
In crowd(s) of 10-50 people*	0.96 (0.83 - 1.12)	0.89 (0.70 - 1.13)	0.354	1.20 (1.04 - 1.39)	1.00 (0.81 - 1.24)	0.967
In crowd(s) of more than 50 people*	1.39 (1.22 - 1.57)	1.21 (1.00 - 1.47)	0.050	1.46 (1.29 - 1.64)	1.32 (1.11 - 1.56)	0.001
Number of children	0.81 (0.76 - 0.86)	0.88 (0.81 - 0.96)	0.003	0.92 (0.86 - 0.97)	1.04 (0.96 - 1.12)	0.338
Contact with other's children*	0.50 (0.44 - 0.56)	0.77 (0.64 - 0.91)	0.003	0.60 (0.53 - 0.68)	0.71 (0.60 - 0.83)	<0.001

Pet (cat, dog or other) in household	0.69 (0.60 - 0.79)	0.81 (0.68 - 0.97)	0.021	0.73 (0.64 - 0.83)	0.83 (0.71 - 0.97)	0.022
Regularly meet people at work	0.30 (0.24 - 0.37)	0.52 (0.37 - 0.73)	<0.001	0.48 (0.39 - 0.58)	0.48 (0.36 - 0.62)	<0.001
Work with pupils, clients or patients	0.32 (0.28 - 0.37)	0.54 (0.45 - 0.65)	<0.001	1.36 (1.20 - 1.54)	1.24 (1.05 - 1.48)	0.014
Wash hands 7 times or more per day	0.47 (0.41 - 0.55)	0.92 (0.74 - 1.14)	0.463	0.95 (0.82 - 1.09)	1.10 (0.92 - 1.32)	0.303
Regularly use hand sanitiser	0.25 (0.22 - 0.29)	0.38 (0.31 - 0.46)	<0.001	0.70 (0.61 - 0.79)	0.63 (0.54 - 0.75)	<0.001
Use gloves in private for protection	0.60 (0.51 - 0.70)	0.54 (0.44 - 0.66)	<0.001	0.47 (0.41 - 0.55)	0.55 (0.46 - 0.65)	<0.001

Legend:

§the last three weeks before symptoms.

*the last two weeks before symptoms or before lockdown.

Table 3a. Risk factors in health professionals

	Bivariate	Multivariable		Bivariate	Multivariable	
	Cases vs Negative controls	Cases vs Negative controls	P-	Cases vs untested volunteer controls	Cases vs untested volunteer controls	P-
	OR (95% CI)	Adj. OR (95% CI)	value	OR (95% CI)	Adj. OR (95% CI)	value
Age in years	1.00 (0.99 - 1.01)	1.00 (0.99 - 1.01)	0.896	0.99 (0.98 - 1.00)	1.01 (1.00 - 1.02)	0.085
Male sex	1.49 (1.10 - 2.04)	0.82 (0.56 - 1.22)	0.323	1.64 (1.21 - 2.22)	0.99 (0.68 - 1.43)	0.946
Close contact with infected§	7.04 (5.46 - 9.07)	3.48 (2.44 - 4.98)	<0.001	13.1 (10.2 - 16.9)	7.09 (4.76 - 10.57)	<0.001
Close contact with likely infected§	6.43 (4.98 - 8.30)	3.29 (2.30 - 4.72)	<0.001	8.27 (6.43 - 10.62)	2.63 (1.76 - 3.92)	<0.001
Chronic disease(s)	0.69 (0.51 - 0.95)	0.78 (0.53 - 1.14)	0.193	0.84 (0.62 - 1.15)	1.11 (0.77 - 1.61)	0.581
Other disease(s)	0.92 (0.68 - 1.25)	1.13 (0.78 - 1.64)	0.511	1.00 (0.74 - 1.35)	1.18 (0.83 - 1.68)	0.350
Monthly visit(s) to health services	0.67 (0.46 - 0.96)	0.80 (0.50 - 1.27)	0.337	0.83 (0.58 - 1.19)	1.02 (0.65 - 1.59)	0.945
Light infection(s) the last 6 months	0.20 (0.16 - 0.26)	0.24 (0.18 - 0.33)	<0.001	0.64 (0.50 - 0.82)	0.71 (0.54 - 0.95)	0.022
Smoker (Past or current)	0.77 (0.59 - 0.99)	0.89 (0.65 - 1.23)	0.491	0.74 (0.57 - 0.96)	0.92 (0.68 - 1.24)	0.572
Fitness: Good	1	1		1	1	
Medium	0.57 (0.44 - 0.73)	0.77 (0.57 - 1.04)		0.62 (0.48 - 0.79)	0.79 (0.59 - 1.05)	
Poor	0.11 (0.04 - 0.35)	0.19 (0.06 - 0.61)	0.001	0.15 (0.05 - 0.46)	0.25 (0.08 - 0.81)	0.010
Visit to grocery store: 0 - 3 times*	1	1		1	1	
4 - 10 times*	0.71 (0.55 - 0.93)	0.77 (0.56 - 1.05)		0.63 (0.48 - 0.81)	0.69 (0.51 - 0.94)	
More than 11 *	0.46 (0.25 - 0.83)	0.54 (0.28 - 1.06)	0.106	0.36 (0.20 - 0.64)	0.46 (0.25 - 0.88)	0.013
Use of public transport: Not once*	1	1		1	1	
1 - 3 times*	1.71 (1.24 - 2.34)	1.81 (1.23 - 2.65)		2.05 (1.50 - 2.81)	1.85 (1.29 - 2.66)	
4 - 10 times*	1.72 (1.21 - 2.46)	1.59 (1.02 - 2.47)		2.46 (1.73 - 3.50)	1.95 (1.29 - 2.94)	
More than 11*	1.37 (0.96 - 1.96)	1.56 (1.00 - 2.45)	0.017	2.12 (1.49 - 3.02)	2.10 (1.38 - 3.20)	<0.001
International flight(s)*	2.13 (1.56 - 2.92)	1.82 (1.23 - 2.70)	0.004	3.23 (2.37 - 4.40)	2.79 (1.91 - 4.07)	<0.001
In crowd(s) of 10-50 people*	0.73 (0.55 - 0.96)	0.70 (0.47 - 1.03)	0.075	0.93 (0.71 - 1.24)	0.84 (0.58 - 1.21)	0.353
In crowd(s) of more than 50 people*	0.95 (0.74 - 1.21)	0.82 (0.58 - 1.14)	0.239	1.13 (0.88 - 1.45)	0.98 (0.71 - 1.34)	0.888
Number of children	0.81 (0.72 - 0.92)	0.88 (0.76 - 1.02)	0.089	0.88 (0.78 - 0.99)	1.07 (0.93 - 1.23)	0.373
Contact with other's children*	0.57 (0.44 - 0.73)	0.82 (0.60 - 1.12)	0.207	0.62 (0.48 - 0.79)	0.72 (0.53 - 0.97)	0.030
Pet (cat, dog or other) in household	0.81 (0.62 - 1.05)	0.98 (0.71 - 1.35)	0.901	0.72 (0.56 - 0.93)	0.83 (0.61 - 1.12)	0.216

Regularly meet people at work	0.32 (0.14 - 0.70)	0.30 (0.11 - 0.78)	0.023	0.26 (0.12 - 0.57)	0.32 (0.13 - 0.80)	0.027
Work with pupils, clients or patients	1.16 (0.77 - 1.74)	1.23 (0.75 - 2.03)	0.399	1.34 (0.90 - 2.00)	1.33 (0.82 - 2.14)	0.230
Wash hands 7 times or more per day	0.50 (0.34 - 0.73)	0.66 (0.42 - 1.05)	0.088	0.56 (0.39 - 0.80)	0.62 (0.40 - 0.97)	0.045
Regularly use hand sanitiser	0.24 (0.16 - 0.36)	0.16 (0.10 - 0.26)	<0.001	0.27 (0.19 - 0.39)	0.20 (0.13 - 0.32)	<0.001
Use gloves in private for protection	0.48 (0.33 - 0.69)	0.49 (0.31 - 0.76)	0.001	0.49 (0.34 - 0.71)	0.52 (0.34 - 0.80)	0.001

Legend:

§the last three weeks before symptoms.


*the last two weeks before symptoms or before lockdown.

Table 3b. COVID-19 patients as a risk factors for health professionals

	Bivariate			Bivariate		
	Cases vs Negative controls (N=319 vs 7395)			Cases vs untested volunteer controls (N=319 vs 19853)		
	OR (95% CI)			OR (95% CI)		
Number of COVID-19 patients treated in ward*						
0	1 (index)			1 (index)		
1-5	1.2 (0.9-1.7)			1.6 (1.2-2.3)		
6-10	1.8 (1.1-3.0)			2.9 (1.7-4.8)		
11-20	1.2 (0.5-2.5)			1.7 (0.8-3.6)		
21-50	1.3 (0.5-3.2)			2.2 (0.9-5.5)		
>51	1.8 (0.7-5.2)			3.7 (1.3-10)		

*Age and gender are included as confounders. Inclusion of all variables in the full model in Table 3a except “Close contact with infected” and “Close contact with likely infected” does not change the trend.

Figure 1. Timeline of the epidemic development in relation to the study population.



Access to test	Test count	39	1,880	8,640
Anyone w symptoms & travel history	✓	Travel the last two weeks		
High-risk* patients with symptoms	✓	✓	✓	✓
Health professionals with symptoms	✓	✓	✓	✓
Hospitalized patients with symptoms	✓	✓	✓	✓

Legend Figure 1: The countries represent the probable origin of infection. Test criteria changed in the study period.^{20,21}

*Above the age of 65 years with cardiovascular or lung disease, cancer, hypertension or diabetes




Figure 2. Recruitment of invited (laboratory results) and volunteers (national TV and social media)

Legend Figure 2.

*Participants tested at Oslo University Hospital, Vestre Viken or Fürst laboratories.

#Minors (n=1207), invalid contact information or people in a registry for those who do not want unsolicited contact (n=3276), invalid test results (n=1135), multiple tests from same person (positive test result, n=1681). Some participants had several reasons for exclusion.



§Did not respond to invitation before April 6th 2020.

‡Through online portal.

¶Overload of system.

∞Minors (n=121), refused (n=464), withdrew (n=2).

**508 of these could be confirmed, Kappa 0.97.



Study participants (n=116,678).

All tested as reported by Norwegian authorities (n=111,299).²⁰

Figure 3. Geographical distribution of study participants and national SARS-CoV-2 cases by April 6, 2020

Legend: Information per province by April 6, 2020. The percentages represent the provincial participation and SARS-CoV-2 prevalence.

Supplementary Material

Table of contents

Supplement 1 – Comparison of tested Invited and Volunteers.....	33
Supplement 2 – Healthcare Professionals with Patient Contact.....	36
Supplement 3 – Sensitivity Analysis	38

Supplement 1 – Comparison of tested Invited and Volunteers

Differences Between Tested Invited Cases and Controls and Volunteers with Self-reported Test Results

A total of 7839 participants were included after they were invited to the study because of a SARS-CoV-2 PCR test (“Invited”). Another 108839 participants volunteered to participate after media coverage of the study. 3875 of these participants self-reported a SARS-CoV-2 PCR test result.

In Table S1a the laboratory confirmed invited cases and controls were compared to the group of volunteers that self-reported a test result. The table shows that the groups were broadly similar. The volunteers used less public transportation and more often lived in a free-standing house than the Invited. The invited were recruited from a relatively urbanized area in Norway whereas the Volunteers came from the whole country including more rural areas.

Table S1a

Variable	Value	Volunteers with a self-reported test result (N=3875)	Invited based on a conclusive positive or negative SARS-CoV-2 test (N=7839)	Total (N=11714)
Mean age in years (Standard Deviation)	Mean	42.9 (11.6)	45.3 (13.6)	44.5 (13.0)
Gender	Male	692 (17%)	2072 (27%)	2764 (24%)
Close contact with infected**	Yes	569 (14%)	1439 (19%)	2008 (17%)
Close contact with likely infected**	Yes	586 (15%)	1335 (18%)	1921 (17%)
Chronic diseases	Yes	1121 (28%)	2301 (30%)	3422 (29%)
Other diseases	Yes	960 (26%)	1777 (25%)	2737 (25%)
Smoker (Past/Current)	Yes	1737 (44%)	3214 (42%)	4951 (43%)
Fitness	Good	1224 (31%)	2844 (37%)	4068 (35%)
	Medium	2406 (60%)	4253 (55%)	6659 (57%)
	Bad	371 (9%)	606 (8%)	977 (8%)
Monthly visits to health system	None	3132 (78%)	5878 (76%)	9010 (77%)
	1-2	756 (19%)	1550 (20%)	2306 (20%)
	3-4	61 (2%)	141 (2%)	202 (2%)
	5 and above	46 (1%)	128 (2%)	174 (2%)
In food store 2 weeks before 13.03.2020 or disease/test	Not once in 2 weeks	64 (2%)	221 (3%)	285 (2%)
	1 - 3 times in 2 weeks	1080 (27%)	2326 (30%)	3406 (29%)
	4 - 10 times in 2 weeks	2504 (63%)	4519 (59%)	7023 (60%)
	11 times or more in 2 weeks	327 (8%)	595 (8%)	922 (8%)
Public transport 2 weeks before 13.03.2020 or disease/test	Not once in 2 weeks	2138 (54%)	2820 (37%)	4958 (43%)
	1 - 3 times in 2 weeks	921 (23%)	1787 (23%)	2708 (23%)
	4 - 10 times in 2 weeks	535 (13%)	1350 (18%)	1885 (16%)
	11 times or more in 2 weeks	385 (10%)	1703 (22%)	2088 (18%)
International flight*	Yes	596 (15%)	1498 (20%)	2094 (18%)
In crowd(s) of 10-50 people*	Yes	1888 (48%)	3721 (49%)	5609 (48%)
Contact with other's children*	Yes	2696 (68%)	4650 (61%)	7346 (63%)
Pet (cat, dog or other) in household	Yes	1791 (45%)	2632 (34%)	4423 (38%)
Regularly meet people at work	Yes	3881 (97%)	7368 (96%)	11249 (96%)

Work with pupils, clients or patients	Yes	2635 (66%)	4102 (53%)	6737 (58%)
Wash hands 7 times or more per day	Yes	3564 (89%)	6593 (86%)	10157 (87%)
Regularly use hand sanitiser	Yes	3568 (89%)	6558 (85%)	10126 (87%)
Light infections last 6 months	Yes	3312 (83%)	6138 (80%)	9450 (81%)
Use gloves in private for protection	Yes	964 (24%)	2385 (31%)	3349 (29%)
Hypertension	Yes	363 (10%)	829 (11%)	1192 (11%)
Diabetes	Yes	98 (3%)	231 (3%)	329 (3%)
Do you know who infected you	Yes	130 (42%)	335 (43%)	465 (43%)
Living quarters	Free standing house	2255 (57%)	2891 (38%)	5146 (44%)
Living quarters	Two households, separate entrances	333 (8%)	660 (9%)	993 (9%)
Living quarters	Several households, separate entrances	448 (11%)	762 (10%)	1210 (10%)
Living quarters	Flat	934 (24%)	3301 (43%)	4235 (37%)
Fever**	Yes	1401 (35%)	2604 (34%)	4005 (34%)
Cough**	Yes	2409 (60%)	4564 (59%)	6973 (60%)
Sore throat**	Yes	2539 (63%)	4593 (60%)	7132 (61%)
Changed sense of smell or taste**	Yes	562 (14%)	1231 (16%)	1793 (15%)
Household member had fever**	Yes	821 (21%)	1512 (20%)	2333 (20%)
Household member had cough**	Yes	1705 (43%)	2913 (38%)	4618 (39%)
Household member had sore throat**	Yes	1515 (38%)	2616 (34%)	4131 (35%)
Household member had changed sense of smell or taste**	Yes	255 (6%)	594 (8%)	849 (7%)
<p>There were few differences between Invited and Volunteers reporting that they were tested for SARS-CoV-2. The Volunteers were more likely to live in a free-standing house and less likely to use public transportation than Invited.</p> <p>Denominator varies as not all answered all questions</p> <p>*the last 2 weeks before symptoms or before lockdown whichever was earliest</p> <p>** the last 3 weeks before answering the questionnaire</p>				

Correspondence Between Self-reported and Laboratory Confirmed SARS-CoV-2 PCR Tests

Table S1b

		Laboratory confirmed SARS-CoV-2 PCR test result			
		Negative for SARS-CoV-2 PCR	Positive for SARS-CoV-2 PCR	Unknown at the time of data collection from lab*	Total
Self-reported test result	Negative for SARS-CoV-2 PCR	6881	0	45	6926
	Positive for SARS-CoV-2 PCR	11	754	21	786
	Waiting for result	141	7	42	190
	Not tested	58	5	23	86
	Total	7091	766	131	7988
<p>Very good correspondence between self-reported test result and laboratory confirmed test results in invited participants (kappa 0.99). * Including inconclusive test results</p>					

To confirm that the Volunteers reported their SARS-CoV-2 PCR test results faithfully, laboratory results from Volunteers already included in the study were obtained from a nearby lab that was not a source of Invited participants. The table shows that these Volunteers had self-reported their test results precisely (kappa 0.97).

Table S1c

		Laboratory confirmed SARS-CoV-2 PCR test result for Volunteer group obtained after data collection.			
		Negative for SARS-CoV-2 PCR	Positive for SARS-CoV-2 PCR	Unknown at the time of data collection from lab*	Total
Self-reported test result from Volunteer group	Negative for SARS-CoV-2 PCR	465	0	1	466
	Positive for SARS-CoV-2 PCR	2	34	3	39
	Waiting for result	2	0	1	3
	Not tested	0	0	0	0
	Total	469	34	5	508
<p>Very good correspondence between self-reported test result and laboratory results in Volunteer participants tested at one particular lab (kappa 0.97). * Including inconclusive test results.</p>					

Supplement 2 – Healthcare Professionals with Patient Contact

Healthcare professionals with and without patient constituted 24% of the study population and healthcare professionals with patient contact at least weekly constituted 18% of the study population. The latter group were tested for SARS-CoV-2 if they had symptoms throughout the study period and was therefore analyzed separately in the paper. In Table S2 healthcare professionals with patient contact are compared with the rest of the study population. Men were underrepresented among healthcare professionals with patient contact.

Table S2

Variable	Value	All participants without patient contact (N=95555)	Healthcare professionals with patient contact# (N=21123)	Total (N=116678)
Mean age in years (Standard Deviation)	Median	46-50 years	41-45 years	41-45 years
Gender	Male	30815 (32%)	2915 (14%)	33730 (29%)
SARS-CoV-2 positive	Yes	837 (0.9%)	262 (1.2%)	1099 (0.9%)
Close contact with infected**	Yes	2851 (3%)	2135 (10%)	4986 (4%)
Close contact with likely infected**	Yes	6667 (7%)	2722 (13%)	9389 (8%)
Chronic diseases	Yes	26275 (28%)	4734 (22%)	31009 (27%)
Other diseases	Yes	21205 (24%)	4391 (22%)	25596 (23%)
Smoker (Past/Current)	Yes	44625 (47%)	8717 (42%)	53342 (46%)
Fitness	Very fit	31521 (33%)	7584 (36%)	39105 (34%)
	Fairly fit	54909 (58%)	12254 (58%)	67163 (58%)
	In bad shape	9037 (10%)	1277 (6%)	10314 (9%)
Monthly visits to health system	None	74511 (78%)	17685 (84%)	92196 (79%)
	43862	18359 (19%)	3069 (15%)	21428 (18%)
	43924	1592 (2%)	180 (1%)	1772 (2%)
	5 and above	992 (1%)	155 (1%)	1147 (1%)
In food store 2 weeks before 13.03.2020 or disease/test*	Not once in 2 weeks	1553 (2%)	175 (1%)	1728 (2%)
	1 - 3 times in 2 weeks	24518 (26%)	5070 (24%)	29588 (25%)
	4 - 10 times in 2 weeks	59431 (62%)	13898 (66%)	73329 (63%)
	11 times or more in 2 weeks	9895 (10%)	1927 (9%)	11822 (10%)
Public transport 2 weeks before 13.03.2020 or disease/test*	Not once in 2 weeks	41732 (44%)	10381 (49%)	52113 (45%)
	1 - 3 times in 2 weeks	21761 (23%)	4624 (22%)	26385 (23%)
	4 - 10 times in 2 weeks	15853 (17%)	2779 (13%)	18632 (16%)
	11 times or more in 2 weeks	16009 (17%)	3287 (16%)	19296 (17%)
International flight*	Yes	11042 (12%)	1746 (8%)	12788 (11%)
In crowd(s) of 10-50 people*	Yes	45092 (47%)	8920 (42%)	54012 (46%)
Contact with other's children*	Yes	56461 (59%)	14113 (67%)	70574 (61%)
Pet	Yes	34764 (36%)	8611 (41%)	43375 (37%)
Regularly meet people at work	Yes	89795 (94%)	20934 (99%)	110729 (95%)
Job with people (pupils, clients, patients)	Yes	16159 (17%)	18415 (87%)	34574 (30%)
Wash hands 7 times or more per day	Yes	72675 (76%)	19523 (93%)	92198 (79%)
Regularly use hand sanitizer	Yes	67431 (71%)	20302 (96%)	87733 (75%)
Light infections last 6 months	Yes	63456 (67%)	15124 (72%)	78580 (67%)
Use gloves in private for protection	Yes	34750 (37%)	4941 (24%)	39691 (34%)

Hypertension	Yes	11835 (13%)	1680 (8%)	13515 (12%)
Diabetes	Yes	2814 (3%)	430 (2%)	3244 (3%)
Do you know who infected you?	Yes	350 (42%)	115 (44%)	465 (43%)
Living quarters	Free standing house	44250 (47%)	10093 (48%)	54343 (47%)
	Two households, separate entrances	8008 (9%)	1758 (8%)	9766 (9%)
	Several households, separate entrances	9704 (10%)	2093 (10%)	11797 (10%)
	Flat	32454 (34%)	6975 (33%)	39429 (34%)
Fever**	Yes	11507 (12%)	2617 (12%)	14124 (12%)
Cough**	Yes	26647 (28%)	6074 (29%)	32721 (28%)
Sore throat**	Yes	29782 (31%)	7508 (36%)	37290 (32%)
Changed sense of smell or taste**	Yes	5556 (6%)	1077 (5%)	6633 (6%)
Household member had fever**	Yes	11668 (12%)	2338 (11%)	14006 (12%)
Household member had cough**	Yes	26344 (28%)	5837 (28%)	32181 (28%)
Household member had sore throat**	Yes	23943 (25%)	5496 (26%)	29439 (25%)
Household member had changed sense of smell or taste**	Yes	3361 (4%)	567 (3%)	3928 (3%)
<p>Comparison between study participants without direct patient contact and healthcare professionals with patient contact at least once per week. Denominator varies as not all answered all questions *the last 2 weeks before symptoms or before lockdown whichever came first ** the last 3 weeks before answering the questionnaire # Healthcare professionals with patient contact at least once per week</p>				

Supplement 3 – Sensitivity Analysis

Sensitivity analysis without high-risk individuals

Participants with a travel history to Italy or Austria and reporting contact with a person with likely or confirmed SARS-CoV-2 infection as well as health professionals working in clinic were excluded from this analysis because they had a likely known source of their infection. The number of remaining cases were 144.

Table S3-1

Variable	Level/Category	Multivariate analysis Positive cases vs Negative controls (OR, 95% CI) (N=3690)	Multivariate analysis Positive cases vs Untested volunteers controls (OR, 95% CI) (N=83486)
Gender	Male	1.73 (1.16 – 2.58)	1.94 (1.33 – 2.83)
Chronic diseases	Yes	1.33 (0.86 – 2.07)	1.66 (1.10 – 2.50)
Other diseases	Yes	0.49 (0.28 – 0.83)	0.65 (0.39 – 1.09)
Smoking	Past/Current	0.69 (0.46 – 1.04)	0.73 (0.50 – 1.07)
Fitness	Good	Reference.	Reference
	Medium	0.99 (0.66 – 1.49)	0.94 (0.64 – 1.37)
	Bad	0.55 (0.22 – 1.35)	0.55 (0.23 – 1.31)
Prior visits in health service	Yes	0.61 (0.36 – 1.04)	1.00 (0.60 – 1.65)
Visits to food store last 2 weeks*	0-3	Reference.	Reference
	4-10	0.62 (0.42 – 0.92)	0.46 (0.31 – 0.66)
	11+	0.22 (0.07 – 0.73)	0.14 (0.04 – 0.44)
Use of public transportation past 2 * weeks	0	Reference.	Reference
	1-3	0.73 (0.45 – 1.19)	0.86 (0.54 – 1.37)
	4-10	0.72 (0.41 – 1.26)	0.88 (0.51 – 1.52)
	11+	0.66 (0.36 – 1.23)	0.86 (0.48 – 1.55)
International flights past 2 weeks*	Yes	0.89 (0.57 – 1.39)	2.71 (1.78 – 4.11)
Being in crowds of 10-50 people past 2 weeks*	Yes	1.31 (0.77 – 2.21)	1.30 (0.80 – 2.14)
Being in crowds of 50+ people last 2 weeks*	Yes	0.98 (0.63 – 1.53)	0.95 (0.63 – 1.43)
Contact with other kids past 2 weeks*	Yes	0.80 (0.53 – 1.20)	0.76 (0.51 – 1.11)
Pet	Yes	0.68 (0.45 – 1.03)	0.78 (0.52 – 1.15)
Regularly meet people at work	Yes/NA	0.78 (0.38 – 1.60)	0.70 (0.36 – 1.38)
Work with pupils, clients or patients	Yes	1.49 (0.93 – 2.39)	2.08 (1.33 – 3.23)
Wash hands 7 times or more per day	7+	1.03 (0.65 – 1.63)	1.32 (0.86 – 2.02)
Regularly use hand sanitiser	Yes	0.57 (0.38 – 0.86)	0.88 (0.60 – 1.29)
Light infections last 6 months	Yes	0.26 (0.18 – 0.38)	0.61 (0.43 – 0.89)
Use gloves in private for protection	Yes	0.44 (0.27 – 0.70)	0.45 (0.29 – 0.71)
Number of children at home	Continuous	0.91 (0.75 – 1.11)	1.04 (0.86 – 1.26)
Age	Continuous	1.00 (0.99 – 1.02)	1.00 (0.99 – 1.02)
<p>The main findings in the study remained robust in multivariate analysis where high-risk individuals were omitted from the case group. However, the confidence intervals are wide because of the low number of cases included in this analyses. CI: confidence interval, OR: odds ratio *the last 2 weeks before symptoms or before lockdown whichever was earliest</p>			

Sensitivity Analysis without Self-reported SARS-CoV-2 PCR Positive Cases

The study was planned as an unmatched case-control study among all patients tested positively and negatively for SARS-CoV-2 in several large laboratories as the cases and controls, respectively. An additional control group of untested volunteers were recruited by self referral. In total, 759 Cases with PCR confirmed SARS-CoV-2, 7080 Controls with a negative SARS-CoV-2 result and 104,964 Volunteer Controls reporting not to have undergone testing for SARS-CoV-2 were recruited. The findings in the Case-Control study were fully in accordance with the somewhat larger cross-sectional study.

Table S3-2


Risk factors in Invited Cases with laboratory confirmed SARS-CoV-2 PCR	Level/Reference	Multivariate analyses Invited positive cases (N=759) vs Invited negative controls (N=7080) (OR, 95% CI) *	Multivariate analyses Invited positive cases (N=759) vs Untested volunteer controls (N=104,964) (OR, 95% CI) *
Age	Continuous	1.01 (1.00 - 1.02)	1.01 (1.01 - 1.02)
Gender	Male	1.70 (1.38 - 2.09)	1.65 (1.37 - 1.99)
Close contact with infected	Yes	4.55 (3.61 - 5.74)	25.12 (20.04 - 31.50)
Close contact with likely infected	Yes	3.04 (2.40 - 3.84)	2.73 (2.18 - 3.42)
Chronic diseases	Yes	0.95 (0.75 - 1.21)	1.25 (1.01 - 1.55)
Other diseases	Yes	0.69 (0.52 - 0.91)	0.73 (0.57 - 0.95)
Monthly visits to health services	Yes	0.87 (0.66 - 1.16)	1.23 (0.95 - 1.59)
Light infections last 6 months	Yes	0.27 (0.22 - 0.33)	0.56 (0.47 - 0.67)
Smoking	Past/Current	0.98 (0.79 - 1.20)	0.91 (0.76 - 1.09)
Fitness	Good	1	1
	Medium	0.65 (0.53 - 0.80)	0.61 (0.51 - 0.73)
	Bad	0.45 (0.27 - 0.74)	0.41 (0.26 - 0.65)
Visits to food store last 2 weeks	0-3	1	1
	4-10	0.57 (0.46 - 0.70)	0.51 (0.43 - 0.62)
	11+	0.49 (0.31 - 0.75)	0.34 (0.23 - 0.51)
Use of public transportation past 2 weeks	0	1	1
	1-3	1.39 (1.08 - 1.80)	1.32 (1.05 - 1.66)
	4-10	1.47 (1.10 - 1.95)	1.41 (1.09 - 1.82)
	11+	1.63 (1.21 - 2.19)	1.46 (1.12 - 1.91)
International flights past 2 weeks	Yes	1.74 (1.39 - 2.18)	3.35 (2.76 - 4.08)
Being in crowds of 10-50 people past 2 weeks	Yes	0.81 (0.61 - 1.09)	0.91 (0.70 - 1.17)
Being in crowds of 50+ people last 2 weeks	Yes	1.25 (0.99 - 1.58)	1.37 (1.11 - 1.69)
Number of children at home	Continuous	0.86 (0.77 - 0.96)	1.02 (0.93 - 1.12)
Contact with other kids past 2 weeks	Yes	0.73 (0.59 - 0.90)	0.68 (0.57 - 0.82)
Pet (cat, dog or other) in household	Yes	0.78 (0.63 - 0.97)	0.81 (0.67 - 0.98)
Regularly meet people at work	Yes/NA	0.53 (0.36 - 0.79)	0.49 (0.35 - 0.68)
Working with people	Yes	0.53 (0.42 - 0.66)	1.17 (0.94 - 1.44)
Wash hands 7 times or more per day	7+	0.82 (0.64 - 1.05)	0.99 (0.80 - 1.22)
Regularly use hand sanitizer	Yes	0.40 (0.32 - 0.50)	0.66 (0.54 - 0.80)
Use gloves in private for protection	Yes	0.59 (0.46 - 0.74)	0.61 (0.49 - 0.75)
Multivariate analysis including only the Invited Cases compared to Negative Controls and Untested Volunteer Controls. The removal of Cases with a self-reported SARS-CoV-2 positive			

result did significantly change any of the study results. The number of Invited Cases was 759.

CI: confidence interval, OR: odds ratio

*the last 2 weeks before symptoms or before lockdown whichever was earliest

Figures



Access to test	Test count	39	1,880	8,640
Anyone w symptoms & travel history	✓	Travel the last two weeks		
High-risk* patients with symptoms	✓	✓	✓	✓
Health professionals with symptoms	✓	✓	✓	✓
Hospitalized patients with symptoms	✓	✓	✓	✓

Figure 1

The countries represent the probable origin of infection. Test criteria changed in the study period.^{20,21}
 *Above the age of 65 years with cardiovascular or lung disease, cancer, hypertension or diabetes




Figure 2

Recruitment of invited (laboratory results) and volunteers (national TV and social media) Legend Figure 2. *Participants tested at Oslo University Hospital, Vestre Viken or Fürst laboratories. #Minors (n=1207), invalid contact information or people in a registry for those who do not want unsolicited contact (n=3276), invalid test results (n=1135), multiple tests from same person (positive test result, n=1681). Some participants had several reasons for exclusion. §Did not respond to invitation before April 6th 2020. ¶Through online portal. ¯Overload of system. ∞Minors (n= 2), refused (n=464), withdrew (n=2). **508 of these could be confirmed, Kappa 0.97.




Figure 3

Study participants (n=116,678). All tested as reported by Norwegian authorities (n=111,299).²⁰
 Geographical distribution of study participants and national SARS-CoV-2 cases by April 6, 2020 Legend:
 Information per province by April 6, 2020. The percentages represent the provincial participation and
 SARS-CoV-2 prevalence.